TG Therapeutics (TGTX) shares tumbled 5.71% in pre-market trading on Monday, August 4, 2025, despite the company reporting positive second-quarter financial results and raising its revenue guidance for its drug Briumvi.
The biotechnology company announced its Q2 2025 financial results early Monday, reporting product revenue of $138.843 million and a net income of $28.187 million. Additionally, TG Therapeutics raised its revenue guidance for Briumvi, its flagship multiple sclerosis treatment.
Despite these seemingly positive developments, investors appear to be reacting negatively, possibly indicating that the results or the raised guidance fell short of market expectations. The pre-market plunge suggests that Wall Street may have been anticipating even stronger performance or more optimistic forecasts from the company.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。